Antibiotic changes in pulmonary exacerbation treatment not beneficial in cystic fibrosis

In patients aged 6 to 21 years with cystic fibrosis receiving pulmonary exacerbation treatment, changing antibiotics was not clinically beneficial, according to results published in Annals of the American Thoracic Society.
“Our findings illustrate that changing IV antibiotics during pulmonary exacerbation treatment among children and adolescents with CF is not associated with clinical improvements, including a larger improvement in pre- to post-pulmonary exacerbation lung function,” Jonathan D. Cogen, MD, MPH, attending physician in the division of pulmonary and sleep medicine at

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart